The Use of L-Menthol in Endoscopic Transpapillary Interventions. Prospective Randomized Dual-Center Study

Aim: to study the effect of L-menthol on duodenal peristalsis, the results of cannulation of the papilla, the effectiveness and safety of endoscopic retrograde transpapillary interventions (ERTI).

Materials and methods. A prospective two-center randomized placebo-controlled trial was carried out from January to November 2022 in two centers. The study included 126 patients, 69 (54.8 %) men and 57 (45.2 %) women, mean age — 62.1 ± 1.8 years. The inclusion criteria were age 18–75 years, indications for ERTI, absence of previous endoscopic papillotomy, absence of allergy to menthol, consent to participate in the study. After randomization, the main group (“L”) included 70 patients, the control group — 56. Patients in group “L” were irrigated with 25 mL (160 mg) of L-menthol (Spectavium), patients in the control group — with 25 mL of saline solution. Peristaltic activity was studied before and three minutes after administration of the drug. The intensity of peristalsis was assessed according to a modified Hiki scale: 0 points — complete absence of peristalsis; 1 point — single peristaltic waves; 2 points — intense peristalsis, little amenable to straightening at maximum insufflation; 3 points — pronounced peristalsis.

Results. Three minutes post-irrigation, the suppression of peristaltic waves was noted in the experimental group “L”: 0 points — 63 (90 %) patients, 1 point — 6 (8.6 %) patients, compared to the control, with no change in peristalsis (p < 0.05). Successful selective cannulation was achieved in 64 (91.4 %) patients of group “L” and in 41 (73.2 %) — of the control group (p < 0.05). Non-cannulation endoscopic papillotomy had to be used in 6 (8.5 %) cases in group “L” and in 14 (25 %) cases in the control group. In general, successful cannulation was achieved in 100 % of patients in group “L”, and in 94.5 % — in the control group (p < 0.05). The duration of the intervention was significantly reduced in group “L” — 40 ± 2.5 vs. 50.3 ± 3.6 min. Among the complications, only intraoperative bleeding was registered (2 (2.9 %) — group “L”, 5 (8.9 %) — the control group), which was eliminated endoscopically in all cases.

Conclusion. The use of L-menthol during ERTI helps to achieve noticeable inhibition of peristalsis, promotes successful cannulation, reduces the intervention time, minimizes the risk of intraoperative complications. Thus, L-menthol has demonstrated its effectiveness and safety, which makes it possible to use it in the arsenal of combating enhanced peristalsis during ERTI.

1. Law R., Baron T.H. ERCP. Gastrointest Endosc. 2013;78(3):428–33. DOI: 10.1016/j.gie.2013.06.018

2. Mohseni S., Bass G.A., Forssten M.P., Casas I.M., Martin M., Davis K.A., et al. Common bile duct stones management: A network meta-analysis. J Trauma Acute Care Surg. 2022;93(5):e155–65. DOI: 10.1097/TA.0000000000003755

3. Facciorusso A., Gkolfakis P., Ramai D., Tziatzios G., Lester J., Crinò S.F., et al. Endoscopic treatment of large bile duct stones: A systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2023;21(1):33– 44e9. DOI: 10.1016/j.cgh.2021.10.013

4. Ding X., Zhang F., Wang Y. Risk factors for post-ERCP pancreatitis: A systematic review and meta-analysis. Surgeon. 2015;13(4):218–29. DOI: 10.1016/j.surge.2014.11.005

5. Afridi F., Rotundo L., Feurdean M., Ahlawat S. Trends in post-therapeutic endoscopic retrograde cholangiopancreatography gastrointestinal hemorrhage, perforation and mortality from 2000 to 2012: A nationwide study. Digestion. 2019;100(2):100–8. DOI: 10.1159/000494248

6. Kumbhari V., Sinha A., Reddy A., Afghani E., Cotsalas D., Patel Y.A., et al. Algorithm for the management of ERCP-related perforations. Gastrointest Endosc. 2016;83(5):934–43. DOI: 10.1016/j.gie.2015.09.039

7. Lee T., Anderson J., Thomas-Gibson S., Rees C. Use of intravenous hyoscine butylbromide (Buscopan) during gastrointestinal endoscopy. Frontline Gastroenterol. 2018;9(3):183– 4. DOI: 10.1136/flgastro-2017-100877

8. Ikegaya H., Saka K., Sakurada K., Nakamura M., Yoshida K. A case of sudden death after intramuscular injection of butylscopolamine bromide. Leg Med (Tokyo). 2006;8(3):194–7. DOI: 10.1016/j.legalmed.2005.11.001

9. González-Mendiola R., Sánchez Fernández C., Prieto Montaño P., Cuevas M., Ceña Delgado M., Sánchez Cano M. Acute urticaria induced by hyoscine butylbromide. Allergy. 2004;59(7):787–8. DOI: 10.1111/j.1398- 9995.2004.00410.x

10. Van Dam J., Catalano M.F., Ferguson D.R., Barnes D.S., Zuccaro G. Jr., Sivak M.V. Jr. A prospective, double-blind trial of somatostatin analog (octreotide) versus glucagon for the inhibition of small intestinal motility during endoscopic retrograde cholangiopancreatography. Gastrointest Endosc. 1995;42(4):321–4. DOI: 10.1016/s0016-5107(95)70130-3

11. Hashimoto T., Adachi K., Ishimura N., Hirakawa K., Katsube T., Kurotani A., et al. Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy — a comparative study with butyl scopolamine bromide. Aliment Pharmacol Ther. 2002;16(1):111–8. DOI: 10.1046/j.1365- 2036.2002.01148.x

12. Herskovitz P.I., Sendovski U. Severe allergic reaction to intravenous injection of glucagon. Radiology. 1997;202(3):879. DOI: 10.1148/radiology.202.3.9051052

13. Grigoleit H.G., Grigoleit P. Gastrointestinal clinical pharmacology of peppermint oil. Phytomedicine. 2005;12(8):607–11. DOI: 10.1016/j.phymed.2004.10.006

14. Ford A.C., Talley N.J., Spiegel B.M., Foxx-Orenstein A.E., Schiller L., Quigley E.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ. 2008;337:a2313. DOI: 10.1136/bmj.a2313

15. Alammar N., Wang L., Saberi B., Nanavati J., Holtmann G., Shinohara R.T., et al. The impact of peppermint oil on the irritable bowel syndrome: A meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019;19(1):21. DOI: 10.1186/s12906-018-2409-0

16. Li J., Lv L., Zhang J., Xu L., Zeng E., Zhang Z., et al. A combination of peppermint oil and caraway oil for the treatment of functional dyspepsia: A systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;2019:7654947. DOI: 10.1155/2019/7654947

17. Amato A., Liotta R., Mulè F. Effects of menthol on circular smooth muscle of human colon: Analysis of the mechanism of action. Eur J Pharmacol. 2014;740:295–301. DOI: 10.1016/j.ejphar.2014.07.018

18. Shavakhi A., Ardestani S.K., Taki M., Goli M., Keshteli A.H. Premedication with peppermint oil capsules in colonoscopy: A double blind placebo-controlled randomized trial study. Acta Gastroenterol Belg. 2012;75(3):349–53.

19. Hiki N., Kaminishi M., Yasuda K., Uedo N., Honjo H., Matsuhashi N., et al. Antiperistaltic effect and safety of L-menthol sprayed on the gastric mucosa for upper GI endoscopy: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Gastrointest Endosc. 2011;73(5):932–41. DOI: 10.1016/j.gie.2010.12.013

20. You Q., Li L., Chen H., Chen L., Chen X., Liu Y. L-menthol for gastrointestinal endoscopy: A systematic review and meta-analysis. Clin Transl Gastroenterol. 2020;11(10):e00252. DOI: 10.14309/ctg.0000000000000252

21. Katsinelos P., Lazaraki G., Chatzimavroudis G., Katsinelos T., Georgakis N., Anastasiadou K., et al. Impact of nitroglycerin and glucagon administration on selective common bile duct cannulation and prevention of post-ERCP pancreatitis. Scand J Gastroenterol. 2017;52(1):50–5. DOI: 10.1080/00365521.2016.1228117

22.